
haohu@um.edu.mo
Tel
+853 8822 8538
Office
E12-1050
Consultation Hours
Mon 15:00-16:00
Tue 15:00-16:00
Hao HU 胡豪
Professor, Institute of Chinese Medical Sciences
Academic Qualifications
- Postdoctoral, University of Montreal
- Ph.D, Sichuan University
- M.A, Sichuan University
- B.A, Harbin Engineering University
Teaching
HSCI4010 | Pharmaceutical Economics and Policy | Undergraduate courses |
CMED7005 | International Business and Law for Medicine | M.Sc. Course |
CMED7029 | Research Methodology | M.Sc. Course |
CMED7032 | Health Industry Innovation | M.Sc. Course |
CMED7034 | Application Methodology for Medicinal Management | M.Sc. Course |
HSCI7008 | Health Systems and Policy | M.Sc. Course |
CMED8011 | Advances in Medicinal Administration | Ph.D. Course |
Research
- Disease Modeling and Simulation
- Health System Modeling
- Pharmacoepidemiology and Pharmacoeconomics
- Researchgate: https://www.researchgate.net/profile/Hao_Hu11
- Google Scholar: https://scholar.google.com/citations?user=vQp5OVYAAAAJ&hl=zh-CN&oi=sra
- Zou H, Xue Y, Chen X, Lai Y, Yao D, Ung COL, Hu H*. Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma. PLOS ONE. 2023; 18(10): e0292239.
- Xue Y, Zou H, Ruan Z, Chen X, Lai Y, Yao D, Ung COL*, Hu H*. Pharmacoeconomic evaluation of anti-obesity drugs for chronic weight management: a systematic review of literature. Frontiers in Endocrinology. 2023;14:1254398.
- Chen X, Shi J, Lai Y, Xue Y, Ung COL*, Hu H*. Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design. Chinese Medicine. 2023;18:58.
- Ruan Z, Jiang Y, Shi H, Jia R, Ung COL, Hu H*. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review. Expert Review of Clinical Pharmacology. 2023; 16(2): 161-176.
- Xue Y, Ruan Z, Ung, COL, Lai Y, & Hu H*. Policy analysis of system responses to addressing and reversing the obesity trend in China: a documentary research. BMC Public Health. 2023; 23(1): 1198.
- Yan X, Zou H, Lai Y, Ung CO, Hu H*. Efficacy and safety of first-line targeted treatment and immunotherapy for patients with biliary tract cancer: a systematic review and meta-analysis. Cancers. 2023;15(1):39.
- Zou H, Lei Q, Yan X, Lai Y, Ung CO, Hu H*. Clinical outcomes associated with monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for advanced hepatocellular carcinoma in real-world practice: a systematic literature review and meta-analysis. Cancers. 2023;15(1):260.
- Lei Q, Yan X, Zou H, Jiang Y, Lai Y, Ung CO, Hu H*. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis. Discover Oncology. 2022;13(1):95.
- Hu H*, Su J, Ma J. Smart hospital innovation: technology, service, and policy. Frontiers in Public Health. 2022;10:845577.
- Lai Y, Wang R, Li W, Zhu H, Fei S, Shi H, Lu N, Ung COL, Hu H*, Han S*. Clinical and economic analysis of Gastrodin injection for dizziness or vertigo: a retrospective cohort study based on electronic health records in China. Chinese Medicine. 2022;17: 6.
- Lin Q, Xue Y, Zou H, Ruan Z, Ung CO, Hu H*. Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology. 2022;15(12):1461-9.
- Liu L, Ruan Z, Ung CO, Zhang Y, Shen Y, Han S, Jia R, Qiao J, Hu H*, Guo L*. Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in China. Diabetes Therapy. 2022; 14(1):93-107.
- Ruan Z, Zou H, Lei Q, Ung COL, Shi H, Hu H*. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(4): 555-574.
- Ruan Z, Ung CO, Shen Y, Zhang Y, Wang W, Luo J, Zou H, Xue Y, Wang Y, Hu H*, Guo L*. Long-term cost-effectiveness analysis of once-weekly semaglutide versus dulaglutide in patients with type 2 diabetes with inadequate glycemic control in China. Diabetes Therapy. 2022; 13:1737-1753.
- Xia C, Yao D, Lai Y, Xue Y, Hu H*. Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems. Chinese Medicine. 2022;17:5.
- Zou H, Ge Y, Lei Q, Ung CO, Ruan Z, Lai Y, Yao D, Hu H*. Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. Hepatology International. 2022; 16:27–37.
- Zou H, Li M, Lei Q, Luo Z, Xue Y, Yao D, Lai Y, Ung COL*, Hu H*. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review. Frontiers in Public Health. 2022;21:767.
- Lai Y, Chen S, Li M, Ung CO, Hu H*. Policy interventions, development trends, and service innovations of internet hospitals in China: documentary analysis and qualitative interview study. Journal of Medical Internet Research. 2021;23(7): e22330.
- Li M, Cheng K, Ku K, Li J, Hu H*, Ung CO*. Factors influencing the length of hospital stay among patients with chronic obstructive pulmonary disease (COPD) in macao population: a retrospective study of inpatient health record. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16:1677.
- Li M, Chen S, Lai Y, Liang Z, Wang J, Shi J, Lin H, Yao D, Hu H*, Ung CO*. Integrating real-world evidence in the regulatory decision-making process: a systematic analysis of experiences in the US, EU, and China using a logic model. Frontiers in Medicine. 2021; 8:778.
- Li M, Chen S, Zhao H, Tang C, Lai Y, Ung CO, Su J*, Hu H*. The short-term associations of chronic obstructive pulmonary disease hospitalizations with meteorological factors and air pollutants in Southwest China: a time-series study. Scientific Reports. 2021;11:12914.
- Ruan Z, Yang L, Shi H, Yue X, Wang Y, Liang M, Hu H*. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. 2021, 21(2):221-233.
- Salem A, Zhong H, Ramos M, Lamotte M, Hu H*. Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China. BMJ open. 2021;11(4):e043664.
- Shi H, Chen X, Liu X, Zhu H, Yu F, Ung CO, Chan WS, Hu H*, Han S*. National drug utilization trend of analgesics in China: an analysis of procurement data at 793 public hospitals from 2013 to 2018. Journal of Pharmaceutical Policy and Practice. 2021; 14:45.
- Leung SW, Hu H. 2016. Evidence-based Research Methods for Chinese Medicine. Springer.
- 胡豪, 张黎明. 2014. 重塑价值逻辑:中国制药产业的业务模式创新. 北京: 清华大学出版社. (Hu H, Zhang LM. 2014. Rebuild Value Logics: Business Model Innovation in the Chinese Pharmaceutical Industry. Beijing: Tsinghua University Press. (In Chinese))